Transformational changes in cancer care can bring forth important innovations, but all those come at a cost, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Transformational changes in cancer care can bring forth important innovations, but all those come at a cost, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Transcript:
How well are practices balancing innovations in cancer care and managing the cost of that care?
The cost of innovation is always high. It's just a challenge because as we make transformational changes, there are a lot of innovations that are out there that are brought forth. There's a lot of companies and other relationships that we like to develop, to try to make our practices more efficient in the value-based world. But all those come at a cost and an expense. Again, when we look at the timing of trying to take on new innovations, and seeing what the return on investment is, we don't see those calculated returns in Oncology Care Model for another year. It makes it difficult to manage the finances of taking on new innovations.
As practices move more towards value-based care and try to curb the rising costs of care, are they turning more to clinical pathways? If not, should they be?
My practice is a strong believer in clinical pathways. We've been a pioneer in the development of clinical pathways for many years. We primarily are engaged in treatment pathways as well as symptom management pathways. Our practice has been engaged with oncology for the last 12, 13, 14 years managing treatment pathways. That's part of the equation of creating value-based care, is making sure that with the complexity of the drug regimens and the cost of some of the newer therapies that we have, is that we are being good stewards of the resources that we have. By looking and developing pathways that are based on the evidence of efficacy and toxicity and cost, that we can develop pathway systems that make all the physicians in our practice more congruent in their choices that are more value-based. Without a doubt, we believe that pathways is part of the value-based model of delivering care.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More